Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesNexalis Therapeutics Ltd

Nexalis Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.008 AUD 0.00(0%)
Last update at 2026-11-10T23:00:00Z
VOLUME
7976
Market Cap
2.02M

Momentum Score

…

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Publicly available information on Nexalis Therapeutics Ltd (ASX: NX1) is limited; the company appears to be an Australian therapeutics small-cap. Long-term growth drivers for firms in this sector include successful clinical development, regulatory approvals, partnerships and financing, which could support commercialisation. Investors may find upside if the company advances assets or secures collaborations, but material information is sparse.
Key risks include clinical and regulatory setbacks, the need for recurrent capital and dilution, limited liquidity for a small-cap listing, and execution risk given the sparse public information.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
1.07M
Revenue Per Share
0.01
Gross Profit TTM
1.07M
Debt / Equity
-
ROE
-
Net Debt
0.30M
ROCE
233.79%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.62M -1.21M -1.44M -1.93M -1.11M
Net income -1.62M -1.21M -1.44M -1.93M -1.11M
Selling general administrative 0.70M 1.04M 1.14M 0.92M 0.61M
Gross profit - - - 0.05M 0.05M
Reconciled depreciation - - - - 0.00M
Operating income -1.48M -1.28M -1.44M -1.93M -1.13M
Interest expense 0.14M - - - -
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.14M 0.07M -0.01M - 0.00M
Net interest income -0.13M - - - 0.00M
Total revenue 0.99M 0.41M 1.21M 0.05M 0.17M
Total operating expenses 2.47M 1.68M 2.64M 1.98M -
Cost of revenue - - - 0.00M 0.12M
Total other income expense net 0.99M - - - 0.01M
Net income from continuing ops -1.62M - - - -1.11M
Net income applicable to common shares -1.62M -1.21M -1.44M -1.93M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1.43M 0.71M 1.58M 2.26M 2.95M
Intangible assets - - 0.00M 0.01M 0.01M
Other current assets - - - - 0.00M
Total liab 2.05M 0.45M 0.91M 0.36M 0.25M
Total stockholder equity -0.62M 0.27M 0.67M 1.90M 2.68M
Other current liab - - - - 0.02M
Common stock 15.15M 14.53M 14.08M 13.93M -
Capital stock 15.15M - - - 12.90M
Retained earnings -15.77M -14.26M -13.41M -12.02M -9.25M
Cash 0.44M 0.19M 0.72M 2.13M 2.80M
Total current liabilities 2.07M 0.78M 0.91M 0.36M 0.25M
Net debt 0.30M - - - -
Short term debt 0.43M 0.03M 0.56M 0.00M -
Short long term debt 0.43M - - - -
Property plant equipment - - - 0.00M -
Total current assets 1.43M 0.71M 1.58M 2.24M 2.93M
Net receivables - - - 0.03M -
Long term debt 0.32M - - - -
Inventory - - - 0.00M 0.04M
Accounts payable 1.46M - - - 0.07M
Non current assets total 0.00M - - - 0.02M
Long term debt total 0.32M 0.00M 0.00M 0.00M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total cashflows from investing activities 0.00M 0.00M 0.00M - -
Net borrowings 0.65M - - - -
Total cash from financing activities 1.13M -0.15M 0.54M 1.18M 2.26M
Net income -1.62M - - -1.90M -1.11M
Change in cash 0.24M -0.52M -1.42M -0.67M 1.08M
Begin period cash flow 0.19M - - 2.80M 1.72M
End period cash flow 0.44M - - 2.13M 2.80M
Total cash from operating activities -0.89M -0.37M -1.96M - -
Issuance of capital stock 0.54M - - 1.20M 2.27M
Other cashflows from investing activities 0.00M 0.00M - - -
Sale purchase of stock 0.54M - 0.00M -0.02M -0.01M
Other cashflows from financing activities -0.06M -0.01M -0.00M - -
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.03M
Change in working capital 0.50M 0.77M 0.44M - -
Free cash flow -0.89M - - -1.85M -1.17M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NX1
Nexalis Therapeutics Ltd		 -
-%		 0.01 - - 1.90 8.55 273.62 -3.53
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Nexalis Therapeutics Ltd

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.

505 Little Collins Street, Melbourne, VIC, Australia, 3000

61 3 8678 4091

https://inhalerx.com.au

Name Title Year Born
Mr. Darryl Davies B.Sc. Chief Executive Officer NA
Dr. Robert Jenny B.A., B.Sc., Ph.D. Chief Scientific Officer NA
Greg Hammond Chief Financial Officer NA
Mr. Srinivasa Rao Suryadevara Executive Vice President 1969
Mr. James Stephen Barrie CPA Company Secretary NA
Mr. Greg Hammond Chief Financial Officer NA
Mr. James Stephen Barrie CPA Company Secretary & Director NA
Mr. Darryl Davies B.Sc. CEO & Interim Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…